Cargando…
Healthcare Costs and Resource Utilization in Patients with Multiple Sclerosis Relapses Treated with H.P. Acthar Gel(®)
INTRODUCTION: Multiple sclerosis (MS) is an autoimmune disorder with large annual costs. This study evaluated utilization and costs for the management of MS relapses with H.P. Acthar(®) Gel (repository corticotropin injection; Acthar; Mallinckrodt) compared to receipt of plasmapheresis (PMP) or intr...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969319/ https://www.ncbi.nlm.nih.gov/pubmed/27312977 http://dx.doi.org/10.1007/s12325-016-0363-0 |
_version_ | 1782445762664202240 |
---|---|
author | Gold, Laura S. Suh, Kangho Schepman, Patricia B. Damal, Kavitha Hansen, Ryan N. |
author_facet | Gold, Laura S. Suh, Kangho Schepman, Patricia B. Damal, Kavitha Hansen, Ryan N. |
author_sort | Gold, Laura S. |
collection | PubMed |
description | INTRODUCTION: Multiple sclerosis (MS) is an autoimmune disorder with large annual costs. This study evaluated utilization and costs for the management of MS relapses with H.P. Acthar(®) Gel (repository corticotropin injection; Acthar; Mallinckrodt) compared to receipt of plasmapheresis (PMP) or intravenous immunoglobulin (IVIG) among patients with MS who experienced multiple relapses. METHODS: We identified patients with MS diagnoses who had relapses treated with intravenous methylprednisolone (IVMP), the first-line treatment for MS relapse. Patients who were treated for the subsequent relapses were eligible for the study. We analyzed 12- and 24-month healthcare utilization and costs among patients who received Acthar prescriptions compared to patients who were treated with PMP/IVIG using generalized linear and logistic regression models to calculate unadjusted and adjusted means and 95% confidence intervals. RESULTS: For the 12-month analysis, a total of 213 patients received Acthar prescriptions and 226 were treated with PMP or IVIG. Patients who received Acthar prescriptions were similar to those who received other treatments in terms of most demographic variables. Acthar recipients had fewer hospitalizations (0.2 vs. 0.4; P = 0.01) and received fewer outpatient services (29 vs. 43; P < 0.0001) but received more prescription medications (36 vs. 30; P < 0.0001) compared to recipients of PMP/IVIG. Patients who received Acthar prescriptions had lower inpatient and outpatient costs ($15,000 lower; P = 0.001; and $54,000 lower; P < 0.0001, respectively) but similar total costs. Similar results were seen in the cohort with 24 months of outcome data. CONCLUSION: Acthar may be a useful treatment option compared to PMP/IVIG for patients with MS experiencing multiple relapses. FUNDING: This study was funded by a grant to the University of Washington from Mallinckrodt Pharmaceuticals. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s12325-016-0363-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4969319 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-49693192016-08-25 Healthcare Costs and Resource Utilization in Patients with Multiple Sclerosis Relapses Treated with H.P. Acthar Gel(®) Gold, Laura S. Suh, Kangho Schepman, Patricia B. Damal, Kavitha Hansen, Ryan N. Adv Ther Original Research INTRODUCTION: Multiple sclerosis (MS) is an autoimmune disorder with large annual costs. This study evaluated utilization and costs for the management of MS relapses with H.P. Acthar(®) Gel (repository corticotropin injection; Acthar; Mallinckrodt) compared to receipt of plasmapheresis (PMP) or intravenous immunoglobulin (IVIG) among patients with MS who experienced multiple relapses. METHODS: We identified patients with MS diagnoses who had relapses treated with intravenous methylprednisolone (IVMP), the first-line treatment for MS relapse. Patients who were treated for the subsequent relapses were eligible for the study. We analyzed 12- and 24-month healthcare utilization and costs among patients who received Acthar prescriptions compared to patients who were treated with PMP/IVIG using generalized linear and logistic regression models to calculate unadjusted and adjusted means and 95% confidence intervals. RESULTS: For the 12-month analysis, a total of 213 patients received Acthar prescriptions and 226 were treated with PMP or IVIG. Patients who received Acthar prescriptions were similar to those who received other treatments in terms of most demographic variables. Acthar recipients had fewer hospitalizations (0.2 vs. 0.4; P = 0.01) and received fewer outpatient services (29 vs. 43; P < 0.0001) but received more prescription medications (36 vs. 30; P < 0.0001) compared to recipients of PMP/IVIG. Patients who received Acthar prescriptions had lower inpatient and outpatient costs ($15,000 lower; P = 0.001; and $54,000 lower; P < 0.0001, respectively) but similar total costs. Similar results were seen in the cohort with 24 months of outcome data. CONCLUSION: Acthar may be a useful treatment option compared to PMP/IVIG for patients with MS experiencing multiple relapses. FUNDING: This study was funded by a grant to the University of Washington from Mallinckrodt Pharmaceuticals. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s12325-016-0363-0) contains supplementary material, which is available to authorized users. Springer Healthcare 2016-06-17 2016 /pmc/articles/PMC4969319/ /pubmed/27312977 http://dx.doi.org/10.1007/s12325-016-0363-0 Text en © The Author(s) 2016 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Research Gold, Laura S. Suh, Kangho Schepman, Patricia B. Damal, Kavitha Hansen, Ryan N. Healthcare Costs and Resource Utilization in Patients with Multiple Sclerosis Relapses Treated with H.P. Acthar Gel(®) |
title | Healthcare Costs and Resource Utilization in Patients with Multiple Sclerosis Relapses Treated with H.P. Acthar Gel(®) |
title_full | Healthcare Costs and Resource Utilization in Patients with Multiple Sclerosis Relapses Treated with H.P. Acthar Gel(®) |
title_fullStr | Healthcare Costs and Resource Utilization in Patients with Multiple Sclerosis Relapses Treated with H.P. Acthar Gel(®) |
title_full_unstemmed | Healthcare Costs and Resource Utilization in Patients with Multiple Sclerosis Relapses Treated with H.P. Acthar Gel(®) |
title_short | Healthcare Costs and Resource Utilization in Patients with Multiple Sclerosis Relapses Treated with H.P. Acthar Gel(®) |
title_sort | healthcare costs and resource utilization in patients with multiple sclerosis relapses treated with h.p. acthar gel(®) |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969319/ https://www.ncbi.nlm.nih.gov/pubmed/27312977 http://dx.doi.org/10.1007/s12325-016-0363-0 |
work_keys_str_mv | AT goldlauras healthcarecostsandresourceutilizationinpatientswithmultiplesclerosisrelapsestreatedwithhpacthargel AT suhkangho healthcarecostsandresourceutilizationinpatientswithmultiplesclerosisrelapsestreatedwithhpacthargel AT schepmanpatriciab healthcarecostsandresourceutilizationinpatientswithmultiplesclerosisrelapsestreatedwithhpacthargel AT damalkavitha healthcarecostsandresourceutilizationinpatientswithmultiplesclerosisrelapsestreatedwithhpacthargel AT hansenryann healthcarecostsandresourceutilizationinpatientswithmultiplesclerosisrelapsestreatedwithhpacthargel |